Navigation Links
Stemedica Announces Completion of Clinical Stem Cell Master Bank
Date:9/14/2010

SAN DIEGO, Sept. 14 /PRNewswire/ -- Stemedica Cell Technologies, Inc., a world leader in adult stem cell manufacturing and research, announced today that it has completed its proprietary master bank of mesenchymal bone marrow-derived stem cells. The master cell bank was manufactured in accordance with FDA Good Manufacturing Practices (cGMP). The cell bank has successfully passed all the necessary safety testing required by the FDA and is in compliance with the U.S. Code of Federal Regulations.  Stem cells from the master bank will be used to support clinical trials in the United States and worldwide. The master bank together with its parent bank has the capacity to treat up to 300,000 patients participating in approved clinical trials.

The master bank has been created at the Company's San Diego cGMP manufacturing facility, which is licensed by the State of California's Department of Public Health, Food and Drug Branch to produce stem cells, drugs and biologic products for human clinical trials.  Stem cells from the master bank will be used in the Company's current FDA-approved clinical trial for ischemic stroke in the United States.  There are over 750,000 strokes each year in the United States resulting in 160,000 deaths. In addition, there currently is no treatment option available for the thousands that are left with severe disabilities.

"Stemedica's stem cells will also be provided to sites in various countries that have already received regulatory approval to conduct clinical trials using Stemedica's products," stated, Nikolai Tankovich, MD, PhD, Stemedica's President and Chief Medical Officer. "We have a pending Investigational New Drug application to conduct a clinical trial outside the United States for vascular dementia, the most common form of dementia.  Alzheimer's represents a subgroup of this condition.  Researchers in the United States will now have access to Stemedica stem cells for preclinical studies; cells with predictability and reproducible potency."

"This is a significant milestone in fulfilling our Company's commitment to provide stem cells for clinical trials designed to help people suffering with medical conditions for which there are no other options," said Maynard Howe, PhD,  Stemedica's Chief Executive Officer. "We will now be able to supply our proprietary stem cells to our research and clinical trial partners worldwide."

The Company is in the process of developing master and parent cell banks for additional stem cell lines including neural cells and retinal pigment epithelial cells produced for human use. Management believes that these master cell and parent cell banks are essential to meet the growing demand for stem cell products worldwide.

About Stemedica Cell Technologies, Inc.

Stemedica Cell Technologies, Inc. (www.stemedica.com) is a specialty biopharmaceutical company that is committed to the development and manufacturing of best-in-class adult stem cells and stem cell factors for use by approved research institutions and hospitals for preclinical and human clinical trials. Stemedica is headquartered in San Diego, California.

For more information regarding this media release or Stemedica Cell Technologies, contact Dave McGuigan at dmcguigan@stemedica.com


'/>"/>
SOURCE Stemedica Cell Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Stemedica Announces the Appointment of Dr. Csar Amescua Garcia as Medical and Regulatory Affairs Director – Latin America
2. Stemedica Announces the Appointment of Dr. Lev Verkh as Chief Regulatory and Clinical Development Officer
3. Stemedica Completes Meeting with the FDA
4. United States Patent and Trademark Office Publishes Stemedica's Patent Application for the Treatment of Diabetic Retinopathy
5. The Jordanian Stem Cell Company Acquires Stem Cell Technology From Stemedica International S.A. - First Clinical Trail Anticipated To Begin Early 2010
6. Stemedica Achieves Major Milestone - Company Receives License to Manufacture Clinical Grade Stem Cells
7. Stemedica Selected By World Stem Cell Summit To Present Scientific Discoveries
8. Stemedica Requests Pre-IND Meeting With FDA
9. Stemedica Signs Scientific Advisory Board Agreement with Leading Pediatric Burn & Wound Care Researcher
10. Renowned Stem Cell Researcher Files Study Results With Stemedica
11. CIRM Completes Briefing Visit to Stemedica Cell Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... BALTIMORE, Md. (PRWEB) , ... October 11, 2017 ... ... for digital pathology, announced today it will be hosting a Webinar titled, “Pathology ... of  Advanced Pathology Associates , on digital pathology adoption best practices and how ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today announced ... to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B ... to cross the cell membrane and bind intracellular STAT3 and inhibit its function. ...
(Date:10/10/2017)... 10, 2017 International research firm Parks Associates announced ... at the TMA 2017 Annual Meeting , October 11 in ... residential home security market and how smart safety and security products impact ... Parks Associates: Smart Home ... "The residential security market has ...
(Date:10/9/2017)... ... ... The award-winning American Farmer television series will feature 3 Bar Biologics in ... 8:30aET on RFD-TV. , With global population estimates nearing ten billion people by ... feed a growing nation. At the same time, many of our valuable resources are ...
Breaking Biology Technology:
(Date:4/13/2017)... UBM,s Advanced Design and Manufacturing event in ... and evolving technology through its 3D Printing and Smart ... the expo portion of the event and feature a ... on trending topics within 3D printing and smart manufacturing. ... will take place June 13-15, 2017 at the Jacob K. ...
(Date:4/11/2017)... N.Y. , April 11, 2017 ... fingerprints, but researchers at the New York University ... College of Engineering have found that partial similarities ... security systems used in mobile phones and other ... thought. The vulnerability lies in the ...
(Date:4/5/2017)... April 5, 2017 Today HYPR Corp. ... the server component of the HYPR platform is officially ... the end-to-end security architecture that empowers biometric authentication across ... has already secured over 15 million users across the ... of connected home product suites and physical access represent ...
Breaking Biology News(10 mins):